Loading...
•
Mar 31, 2022
Precigen Q1 2022 Earnings Report
Reported first quarter 2022 financial results and business updates.
Key Takeaways
Precigen reported a 31% increase in total revenues compared to the quarter ended March 31, 2021, driven by higher product and service revenues from Trans Ova and Exemplar. The company's loss from continuing operations improved to $19.3 million, or $(0.10) per basic share, compared to $21.8 million, or $(0.11) per basic share, in 2021.
Received Fast Track designation for PRGN-3006 UltraCAR-T®.
Initiated Phase 1b expansion arm for PRGN-3006 UltraCAR-T® at Dose Level 3 with lymphodepletion.
Initiated dosing in patients at Dose Level 3 via intravenous infusion with lymphodepletion in the PRGN-3005 UltraCAR-T® Phase 1 study.
Initiated Phase 2 study for PRGN-2012 AdenoVerse™ Immunotherapy as an adjuvant treatment in patients with recurrent respiratory papillomatosis.
Precigen
Precigen
Forward Guidance
Precigen is focused on enhancing its financial position, expanding financial flexibility, and extending its cash runway to achieve near-term objectives and intends to expound on these initiatives as the year progresses.